Max Healthcare Institute Ltd Q1 FY27 Earnings Call Summary

Event Participants

Executives (3)

Abhay Suri, Chief Financial Officer, Keshav Gupta, Senior Director, Growth, M&A, and Business Planning, Yogesh Sareen, Senior Director and Chief Financial Officer

Analysts (11)

Abdul Qadir Puranwala, Alankar Garude, Ankur (Individual Investor), Ashutosh Kumar Jha, Bino Pathiparampil, Damyanti Kerai, Karan Vora, Neha Manpuria, Saurabh Kapadia, Sidharth Negandhi, Vivek Agrawal

Financials & KPIs

Geographic & Segment Commentary

Delhi NCR (Max Smart, Nanavati Max, Vaishali, Dwarka, Patparganj): Max Smart has operationalized 50% of its 400-bed brownfield tower with occupancy at ~80%; remaining 50% to be handed over this quarter. Nanavati Max's remaining 50 beds to be operationalized in Q2, with Phase 2 expansion (271 beds) commenced. Board approved ₹425 crores capex for a 202-bed brownfield tower at Vaishali (existing 387 beds), construction commenced, commissioning expected before FY30. 260-bed Dwarka and 400-bed Patparganj projects on track for FY29-FY30 commissioning.

East India (Bhubaneswar/Kalinga): Post-acquisition, Kalinga Hospital contributed ₹19 crores revenue and ₹2 crores EBITDA with 50% occupancy and RPOB of ₹35,000. Pre-acquisition FY26 revenues were ₹154 crores. Turnaround expected over 12 months with focus on operations integration, renovation, technology upgrades, and clinical programs. Minority shareholders (39%) have filed litigation seeking share purchase; management states shares are "not transactable" per legal counsel.

Pune (Greenfield): SPV acquired, now a subsidiary. 450-bed project received IOD, commissioning expected by FY30. Net debt increase of ₹153 crores includes put option liability for balance stake in Yerwada.

Lucknow, Noida, Nagpur (Acquired Hospitals): All three acquisitions described as "successful" with high occupancy ramp-up, revenue, and profitability growth. Moving towards capacity expansion in all three (100 beds at Lucknow, 100 beds at Nagpur), with brownfield expansion leading "straight to the bottom line."

Max@Home and Max Lab (SBUs): Max@Home revenue at ₹78 crores (+32% YoY), offering 16 specialized service lines across 15 cities with 56% repeat transactions. Max Lab revenue at ₹58 crores (+20% YoY), serving 6+ lakh patients in 60+ cities.

Company-Specific & Strategic Commentary

Medical Education Entry: Board has granted in-principle approval to enter medical education business, following National Medical Commission's draft notification allowing for-profit companies to open medical colleges. Management estimates ₹300 crores investment for a 150-seat medical college, targeting ROC of 25-30%+. Plans to leverage existing campuses (27-acre Lucknow campus, Delhi, Bhubaneswar) and existing DNB training infrastructure (600+ students). Funding entirely through internal accruals. Commercial operations expected "over the next few years"; open to acquisitions to accelerate.

Research Ecosystem Development: Established standalone Max Research Center; has conducted 750+ clinical trials, completed 2,200+ investigator-initiated studies, published ~3,500 papers in indexed journals, secured 30+ competitively funded research projects. Recent grants include ICMR Center for Advanced Research in Precision Diabetes, ANRF MAHA MedTech Mission, DBT European Union Dengue Program, India AI Mission initiative, and National Cancer Grid.

Capacity Expansion Pipeline: ~2,900+ beds coming on stream FY27-FY30 across 10 projects including: 100 beds Lucknow (next 2 quarters), 500 beds Sector 56 Gurgaon (phased commissioning by end of 2026), 250 beds Bhubaneswar (12 months), 400 beds Zirapur Mohali (FY28), 200 beds Pitampura (FY29), 400 beds Patparganj (end FY29), 450 beds Pune (FY30).

CGHS Reimbursements & Institutional Payer Mix: CGHS benefits flowing since June onwards, on track for ~₹140 crores annual run-rate. Institutional business share intentionally declining (concerted effort), expected to continue trending down with existing infrastructure. Oncology normalization expected from Q3 onwards with full normalization by Q4 FY27.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

Parliamentary Committee Report

• Question: Thoughts on the recent parliamentary standing committee recommendations for the healthcare sector, including FDI caps? (Damayanti Kerai, HSBC)
• Answer: The report speaks about affordability, but both new hospital bed need and viability must go hand in hand. No outreach was made to hospitals by the committee. Sector requires a lot more capital and an environment that is viable and conducive to investment. Management expects ministries to "look into the balance." (Abhay Suri)

Kalinga Hospital Turnaround Plan

• Question: What is the headroom for improvement in profitability profile and RPOB once changes are implemented? (Damayanti Kerai, HSBC)
• Answer: With currently 50% occupancy and ₹35,000 RPOB, a 50-80% enhancement in both is possible. Plan involves renovating infrastructure, upgrading technology, and enhancing clinical programs over next year. Building an additional 200-250 beds alongside. This is "the same sort of route" taken with prior acquisitions in Lucknow and Noida—a proven playbook. (Abhay Suri)

Max Smart Ramp-up

• Question: Since commissioned beds are already at 80% occupancy, shouldn't incremental EBITDA be high from Q1 itself? (Neha Manpuria, BofA Securities)
• Answer: New hospital trajectory is standard: ramp up occupancy using lower RPOB to build revenue while bearing costs, then improve RPOBs, then achieve breakeven, then profitability. "By the second, third quarter of operation, you are there." First revenues, then profitability, then EBITDA ramp-up overtakes revenue ramp-up. (Abhay Suri)

Nanavati Max Phase 1 and Phase 2

• Question: How are commissioned beds performing, and what's the Phase 2 timeline? (Neha Manpuria, BofA Securities)
• Answer: Opened beds at ~80% occupancy; hospital is further along trajectory than Max Smart—occupancy happened before revenue and EBITDA is catching up. Phase 2 works started; requires shutting down 100-odd existing beds and will take ~2.5 years. Phase 1 EBITDA will catch up to corporate average—"You get there." (Abhay Suri)

Medical Education Business

• Question: What is the capital commitment and returns profile for medical colleges? (Viraj Shah, PGIM India Mutual Fund)
• Answer: ~₹300 crores for a 150-seat medical college, targeting ROC of 25-30%+. Less than 2% of NEET-qualified students find medical college places—government impetus to increase seats. Prerequisite is having a hospital for training. Max already trains 600+ DNB students, has campuses in Delhi, Lucknow, Bhubaneswar. "Almost backward integration." Plans to start at Lucknow first. (Abhay Suri, Yogesh Sareen)

Kalinga Litigation

• Question: On the Bhubaneswar acquisition, there have been litigations with previous promoters. What's the status? (Bino Pathiparampil, Elara Securities)
• Answer: Not promoters—minority shareholders (39% equity) based outside India, facing liquidation proceedings in UAE. Their shares are "not transactable" per legal counsel. They've filed plea to force buyout; Max's counter is shares are "untouchable" until court orders sale. Max has full control of the company. (Yogesh Sareen)

Medical College Structure and Doctor Supply

• Question: Will medical college be part of the consolidated entity, and is this response to future doctor shortage? (Karan Vora, Goldman Sachs)
• Answer: 100% subsidiary of the listed entity with all economic interest inside (unless a PE round is done outside). Doctor supply is "a little too far out" as rationale—benefit is good stream of resident doctors/DNB. Growth is imperative; without it, clinicians and management will move out. (Abhay Suri)

CGHS Run-rate

• Question: Are we on track for the ₹140 crore CGHS number for this year, and how much in Q1? (Karan Vora, Goldman Sachs)
• Answer: On track; super specialty rates flowing from June onwards. ~₹140 crores divided by 4 run-rate from June onwards is valid. (Yogesh Sareen)

Oncology Decline and Institutional Business

• Question: When will oncology growth return to earlier levels, and why is Max impacted more than peers? (Vivek Agrawal, Citigroup)
• Answer: Oncology normalizes from Q3 onwards (full by Q4) as the new MoA was signed in October. Max had largest oncology franchise (25%+ of revenue) and largest CGHS/institutional share due to Delhi presence—hence higher impact. Institutional payer mix expected to continue declining by "concerted effort." (Abhay Suri, Yogesh Sareen)

Impact of New Capacity on OpEx and Margins

• Question: With new beds at Nanavati and Smart, will OpEx increase materially until Gurgaon comes up? (Alankar Garude, Kotak Institutional Equities)
• Answer: No material increase expected. The large indirect cost increase is due to new capacities (Mohali, Nanavati, Smart, Bhubaneswar). Revenue will increase and EBITDA will flow through. On net debt: will marginally go up by end of year due to ongoing CapEx (Shahid Path ₹475 crores, Vaishali ₹424 crores approvals), but 3-4 years down the line should have funded CapEx and paid down debt. (Abhay Suri, Yogesh Sareen)

Free Cash Flow Bridge

• Question: EBITDA grew 15% but free cash flow only 3%—what's the bridge? (Ashutosh Kumar Jha, Balyasny Asset Management)
• Answer: AR buildup of ~₹250 crores due to DSO increase from 87 to 95 days (CGHS new portal not processing bills for a period). ETR also up. Cash conversion at ~56% vs typical 62-65%. Should normalize as new portal collections commence. (Yogesh Sareen)

Industry Long-term Growth Potential

• Question: Can top 2-4 chains each reach 100,000 beds in 20 years? (Ankur, Individual Investor)
• Answer: No—total beds in India are ~100,000; top 3 players at 100,000 each would mean 300,000 beds or "complete consolidation." Execution and capital requirements are "big, big challenges." Larger hospitals growing 10x in 2 decades is not viable. Max doubling every 4-5 years is sustainable; RPOB growth will always be superior to inflation due to innovation in novel treatments. (Abhay Suri)

Key Takeaway

Max Healthcare reported a steady Q1 FY27 with network revenue of ₹2,982 crores (+16% YoY), operating EBITDA of ₹704 crores (+15% YoY), and PAT of ₹357 crores, despite margin compression to 24.8% from new brownfield commissioning (Max Smart at 80% occupancy on opened beds) and the Kalinga acquisition. The oncology drag from CGHS drug discontinuation (share down to 22% from 26%) should normalize by Q4 FY27, while management expects institutional payer mix to continue declining by design. Management is executing an aggressive ~2,900-bed expansion pipeline across 10 projects through FY30, with ₹425 crores approved for Vaishali and the Pune SPV now a subsidiary. New strategic initiatives include entry into medical education (₹300 crores per 150-seat college, targeting ROC of 25-30%+) and a newly established Max Research Center, both reinforcing the "backward integration" thesis of building clinical and academic capabilities. Free cash flow conversion lagged at 56% due to CGHS portal-related AR buildup (DSOs at 95 days), which management expects to normalize. Key watch points include the Kalinga minority litigation, September-October insurance renewals (6% automatic price revision), and margin recovery trajectory as new capacities ramp through the second half of FY27.